Cancer

Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides

SHELTON, CT / ACCESS Newswire / September 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

Cosmos Health’s Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline

Contract manufacturing pipeline surpasses $20 million in implied revenue at wholly owned subsidiary Cana Laboratories, representing over $18 million in...

NexTel Medical Corp. Showcases Pioneer Exosome Technologies and Diagnostic Innovations at Leading Healthcare Conference

Company highlights ongoing clinical developments in traumatic brain injury (TBI) therapeutics and non-invasive cancer screening, sparking key vendor collaboration discussions....

CancerIQ Deepens EHR Integrations to Identify and Guide More Patients Through Cancer Screening, Testing and Surveillance

A redesigned patient experience drives engagement from prevention through survivorship, while chart-aware risk intelligence surfaces guideline-based recommendations in EHR workflowsCHICAGO,...

Aetna Expands Bundled Oncology Prior Authorizations, Easing Provider Burden and Accelerating Member Access to Care

Oncology bundling to support all eligible Medicaid members for all cancer typesFull roll-out across all Aetna businesses in 2027Originally published...

Amberstone Biosciences and Henlius Enter into Collaboration and License Agreement for Conditionally Activated T-Cell Engagers for Solid Tumors

IRVINE, Calif., Sept. 24, 2026 /PRNewswire/ -- Amberstone Biosciences, Inc., a preclinical-stage oncology company developing pH-gated, tumor-activated T-cell engagers (TCEs),...

error: Content is protected !!